Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: A proteomic analysis

Cancer Genomics and Proteomics

Volumn 5, Issue 3-4, 2008, Pages 137-150

  Patel, Bhavinkumar B ^a   He, Yin A ^a   Li, Xin Ming ^a   Frolov, Andrey ^b   Vanderveer, Lisa ^a   Slater, Carolyn ^a   Schilder, Russell J ^a   Von Mehren, Margaret ^a   Godwin, Andrew K ^a   Yeung, Anthony T ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Kentucky   (United States)

Author keywords

Imatinib mesylate; Ovarian cancer; PDGFR; Proteomics

Indexed keywords

ABELSON KINASE; ACTIN; BCR ABL PROTEIN; CYTOSKELETON PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL JUNCTION; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MASS SPECTROMETER; OVARY CANCER; PH; PROTEIN EXPRESSION; PROTEOMICS; RECURRENT DISEASE; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MASS SPECTROMETRY; OVARIAN NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 46849094734     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
3. Bookman MA: Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21: 149s-167s, 2003.
4. Apte SM, Bucana CD, Killion JJ, Gershenson DM and Fidler I: J. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 93: 78-86, 2004.
5. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M and Oberg K: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53: 4550-4554, 1993.
6. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C and Donner DD: Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25: 2060-2069, 2006.
7. Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE and Alberts DS: Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 36: 242-249, 2005.
8. Matei D, Chang DD and Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 10: 681-690, 2004.
9. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
10. Buchdunger E, O'Reilly T and Wood J: Pharmacology of imatinib (STI571). Eur J Cancer 38: S28-36, 2002.
11. Dushkin H and Schilder RJ: Imatinib mesylate and its potential implications for gynecologic cancers. Curr Treat Options Oncol 6: 115-120, 2005.
12. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA and DeWeese TL: Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology 69: 526-31, 2007.
13. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF and Gershenson DM: Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101: 126-31. Epub 2005 Nov 3, 2006.
14. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S and Boyett JM: Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 9: 145-160. Epub 2007 Feb 9, 2007.
15. Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM and Kohn EC: A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110: 309-317, 2007.
16. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL and Ajani JA: Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13:234-240, 2007.
17. Alberts DS, Liu PY, Wilczynski SP, Jang A, Moon J, Ward JH, Beck JT, Clouser M and Markman M: Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer, 17: 784-788, 2007.
18. Joensuu H: Gastrointestinal stromal tumor (GIST). Ann Oncol, 17: x280-286, 2006.
19. Tarn C and Godwin AK: Molecular research directions in the management of gastrointestinal stromal tumors. Curr Treat Options Oncol 6: 473-486, 2005.
20. Tarn C and Godwin AK: The molecular pathogenesis of gastrointestinal stromal tumors. Clin Colorectal Cancer 6: S7-17, 2006.
21. Carrette O, Burkhard PR, Sanchez JC and Hochstrasser DF: State-of-the-art two-dimensional gel electrophoresis: a key tool of proteomics research. Nat Protoc 1: 812-823, 2006.
22. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R and Weiss W: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21: 1037-1053, 2000.
23. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA and Hamilton TC: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
24. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, von Mehren M, Eisenberg B and Godwin AK: Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2: 699-709, 2003.
25. Li XM, Patel BB, Blagoi EL, Patterson MD, Seehozer SH, Zhang T, Damle S, Gao Z, Boman B and Yeung AT: Analyzing alkaline proteins in human colon crypt proteome. J Proteome Res 3: 821-833, 2004.
26. Patel BB, Li XM, Dixon MP, Blagoi EL, Seeholzer SH, Chen, Y, Miller CG, He YA, Tetruashvily M, Chaudhry AH, Ke E, Xie J, Cooper H, Bellacosa A, Clapper ML, Boman BM, Zhang T, Litwin S, Ross EA, Conrad P, Crowell JA, Kopelovich L, Knudson A and Yeung AT: Searchable High-Resolution 2D Gel Proteome of the Human Colon Crypt. J Proteome Res 6: 2232-2238, 2007.
27. Al-Shahrour F, Diaz-Uriarte R and Dopazo J: FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics 20: 578-580, 2004.
28. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM and Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29, 2000.
29. Kanehisa M, Goto S, Kawashima S, Okuno Y and Hattori M: The KEGG resource for deciphering the genome. Nucleic Acids Res 32: D277-280, 2004.
30. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, Gandhi TK, Chandrika KN, Deshpande N, Suresh S, Rashmi BP, Shanker K, Padma N, Niranjan V, Harsha HC, Talreja N, Vrushabendra BM, Ramya MA, Yatish AJ, Joy M, Shivashankar HN, Kavitha MP, Menezes M, Choudhury DR, Ghosh N, Saravana R, Chandran S, Mohan S, Jonnalagadda CK, Prasad CK, Kumar-Sinha C, Deshpande KS and Pandey A: Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res 32: D497-501, 2004.
31. Janssens V and Goris J: Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439, 2001.
32. Millward TA, Zolnierowicz S and Hemmings BA: Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24: 186-191, 1999.
33. Van Hoof C and Goris J: Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim Biophys Acta 1640: 97-104, 2003.
34. Cohen PT: Protein phosphatase 1-targeted in many directions. J Cell Sci 115: 241-256, 2002.
35. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C and Cobb MH: MAP kinases. Chem Rev 101:2449-2476, 2001.
36. Robinson-White A, Hundley TR, Shiferaw M, Bertherat J, Sandrini F and Stratakis CA: Protein kinase-A activity in PRKARIA-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet 12: 1475-1484, 2003.
37. Robinson-White AJ, Leitner WW, Aleem E, Kaldis P, Bossis I and Stratakis CA: PRKARIA inactivation leads to increased proliferation and decreased apoptosis in human B lymphocytes. Cancer Res 66: 10603-10612, 2006.
38. Jiang PS and Yung BY: Down-regulation of nucleophosmin/B23 mRNA delays the entry of cells into mitosis. Biochem Biophys Res Commun 257: 865-870, 1999.
39. You BJ, Huang IJ, Liu WH, Hung YB, Chang JH and Yung BY: Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol 360: 683-690, 1999.
40. Paunesku T, Mittal S, Protic M, Oryhon J, Korolev SV, Joachimiak A and Woloschak GE: Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol, 77: 1007-1021, 2001.
41. Steensgaard P, Garre M, Muradore I, Transidico P, Nigg EA, Kitagawa K, Earnshaw WC, Faretta M and Musacchio A: Sgtl is required for human kinetochore assembly. EMBO Rep 5: 626-631, 2004. Epub 2004 May 7, 2004.
42. Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J and Cheng X: Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol Cell Proteomics 6: 294-304, 2007. Epub 2006 Nov 16, 2007.
43. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z and Vanderhyden BC: A phase II evaluation of imatinib mesylate (IND #61135, NSC #716051) in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. J Clin Oncol, in press, 2008.
44. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-310, 2007.
45. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L and DePinho RA: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290, 2007. Epub 2007 Sep 13, 2007.